Hemastatx is committed to bringing innovation to patients with severe and underserved bleeding disorders. Our lead program, HMX-001, is a first-in-class antibody therapy designed to address the root cause of severe bleeding episodes in patients with von Willebrand factor (VWF) disorders.

Betta Scientific is a Life Sciences consultancy. We support start-ups and established companies in entering international markets. Our clients rely on us to design and execute global go-to-market strategies, build international distribution networks, and accelerate revenue generation across borders.

Biodelphis Therapeutics is a Swiss biotech startup, spinoff of EPFL. We developed a new generation of protease inhibitors with enhanced potency and safety, exhibiting all the qualities needed to become first-in-class drugs for the treatment of cancer, autoimmune diseases and bone diseases.